Skip to main content
×
×
Home

Sertraline in the treatment of panic disorder: A multi-site, double-blind, placebo-controlled, fixed-dose investigation

  • Peter D. Londborg (a1), Robert Wolkow (a2), Ward T. Smith (a3), Eugene Duboff (a4), Donald England (a5), James Ferguson (a6), Murray Rosenthal (a7) and Charles Weise (a8)...
Abstract
Background

This study compared the efficacy and safety of sertraline to placebo in treating panic disorder.

Method

178 out-patients with panic disorder who exhibited at least four panic attacks during the four weeks prior to screening and three during the two weeks of lead-in were randomly assigned to 12 weeks of double-blind treatment with sertraline (50, 100 or 200 mg) or placebo.

Results

Sertraline was superior to placebo in reducing the number of panic attacks, situational attacks, unexpected attacks, limited symptom attacks, and time spent worrying (all P < 0.01) and the Hamilton Anxiety Scale (P < 0.05), although Clinical Global Impression (Improvement) did not significantly differentiate groups at 12 weeks and at end-point. No serious adverse events were associated with sertraline. No dose relationship was found for adverse events; overall drop-out rates were not different for sertraline or placebo, although more sertraline-treated subjects discontinued for adverse events, typically early in the study. Only dry mouth and ejaculation failure (primarily ejaculation delay) were associated significantly with sertraline. Conclusions Sertraline was effective and safe in reducing panic attacks. Higher doses were no more effective than the 50 mg dose.

Copyright
Corresponding author
Dr P. Londborg, Summit Research Network, 901 Boren Avenue, Suite 1800, Seattle, WA, USA 98104. Fax: 206 624 6975
Footnotes
Hide All

Declaration of interest

R.W. is a Senior Associate Medical Director at Pfizer Inc.

Footnotes
References
Hide All
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). Washington. DC: APA.
Black, D. W. Werner, R. Bowers, W. et al (1993) A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Archives of General Psychiatry, 50, 4450.
Cassano, G. B. Toni, C. Petracca, A. et al (1994) Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. Europea. Neuropsychopharmacology, 4, 4753.
Den-Boer, J. A. Westenberg, H. G. De Leeuw, A. S. et al (1995) Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. International Clinical Psychopharmacology, 4, 4752.
Greist, J. H. Chouinard, G. Duboff, E. et al (1995) Double-blind parallel comparison of three doses of sertraline and placebo in outpatients with obsessive compulsive disorder. Archives of General Psychiatry, 52, 289295.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub (ADM). Rockville, MD: National Institute for Mental Health.
Hamilton, M. (1959) The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 5055.
Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social Clinical Psychology, 6, 278296.
Hoehn-Saric, R. McLeod, D. R. & Hipsley, P. A. (1993) Effect of fluvoxamine on panic disorder. Journal of Clinical Psychopharmacology, 13, 321326.
Louie, A. K. Lewis, T. B. & Lannon, R. A. (1993) Use of low-dose fluoxetine in major depression and panic disorder. Journal of Clinical Psychiatry, 54, 435438.
Nagy, L. M. Morgan, C. A. III Southwick, S. M. et al (1993) Open prospective trial of fluoxetine for posttraumatic stress disorder. Journal of Clinical Psychopharmacology, 13, 107113.
Noyes, R. Jr Garvey, M. J. Cook, B. L. et al (1989) Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. Journal of Clinical Psychiatry, 50, 6369.
Oehrberg, S. Christiansen, P. E. Behnke, K. et al (1995) Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. British Journal of Psychiatry, 167, 374379.
Pecknold, J. C. (1993) Discontinuation reactions to alprazolam in panic disorder. Conference on Panic and Anxiety: A Decade of Progress (1990, Geneva. Switzerland). Journal of Psychiatric Research, 27 (suppl. 1), 155170.
Pecknold, J. C. Luthe, L. Iny, L. et al (1995) Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study. Psychiatry Neuroscience, 20, 193198.
Pounds, R. (1992) A review of the medical and social consequences of generalized anxiety disorder and panic disorder. Journal of the Louisiana State Medical Society, 144, 479483.
Rosenberg, R. (1993) Drug treatment of panic disorder. Pharmacology and Toxicology, 72, 344353.
Salzman, C. (1993) Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse (Review). Journal of Psychiatric Research, 27 (suppl. 1), 97100.
Sheehan, D. V. (1989) Diagnosis and psychiatry: examination of the psychiatric patient. In Comprehensive Textbook of Psychiatry (5th edn) (eds Kaplan, H. I. & Sadock, B. J.). Baltimore, MD: Williams and Wilkins.
Spitzer, R. L. Williams, J. B. W. Gibbons, M. et al (1990) Structured Clinical Interview for DSM-III-R. Washington, DC: American Psychiatric Press.
Svebak, S. Cameron, A. & Levander, S. (1990) Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side-effects. Journal of Clinical Psychiatry, 51 (suppl.). 14–17, 5053.
Wade, A. Lepoto, U. Koponen, H. et al (1997) The effect of citalopram in panic disorder. British Journol of Psychiatry, 170, 549553.
Weinstein, R. S. (1995) Panic disorder. American Family Physician, 52, 1999–2000, 20552063. 2067–2068.
Weissman, M. M. (1988) The epidemiology of panic disorder and agoraphobia. American Psychiatric Press Review of Psychiatry (Vol. 7) (eds Frances, A. J. & Hales, R. E.), pp. 5466. Washington, DC: American Psychiatric Press.
Wolkow, R. Alderman, J. Johnson, H. et al (1996) Sertraline treatment of children and adolescents with obsessive compulsive disorder or depression. X World Congress of Psychiotry Abstracts, 2, 145.
Yeragani, V. K. Pohl, R. Baton, R. et al (1992) Imipramine-induced jitteriness and decreased serum iron levels. Neuropsychobiology, 25, 810.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Sertraline in the treatment of panic disorder: A multi-site, double-blind, placebo-controlled, fixed-dose investigation

  • Peter D. Londborg (a1), Robert Wolkow (a2), Ward T. Smith (a3), Eugene Duboff (a4), Donald England (a5), James Ferguson (a6), Murray Rosenthal (a7) and Charles Weise (a8)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *